This page in English

Mattias Carlsten

Forskarassistent

Besöksadress : M 54, Karolinska Universitetssjukhuset Huddinge 141 86 Stockholm
Postadress : Institutionen för medicin, Huddinge (MedH), H7, Enheten för hematologi, M 54, Karolinska Universitetssjukhuset Huddinge 141 86 Stockholm
Leveransadress : M 54, Karolinska Universitetssjukhuset Huddinge 141 86 Srockholm

Om mig

Se sidan på engelska 

Publikationer

Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma
Carlsten M, Korde N, Kotecha R, Reger R, Bor S, Kazandjian D, et al
Clinical cancer research : an official journal of the American Association for Cancer Research 2016;22(21):5211-5222

Efficient mRNA-Based Genetic Engineering of Human NK Cells with High-Affinity CD16 and CCR7 Augments Rituximab-Induced ADCC against Lymphoma and Targets NK Cell Migration toward the Lymph Node-Associated Chemokine CCL19
Carlsten M, Levy E, Karambelkar A, Li L, Reger R, Berg M, et al
Frontiers in immunology 2016;7():105-

mRNA Transfection to Improve NK Cell Homing to Tumors
Levy Er, Carlsten M, Childs Rw
Methods in molecular biology (Clifton, N.J.) 2016;1441():231-40

Coordinated expression of DNAM-1 and LFA-1 in educated NK cells
Enqvist M, Ask Eh, Forslund E, Carlsten M, Abrahamsen G, Béziat V, et al
Journal of immunology (Baltimore, Md. : 1950) 2015;194(9):4518-27

Genetic Manipulation of NK Cells for Cancer Immunotherapy: Techniques and Clinical Implications
Carlsten M, Childs Rw
Frontiers in immunology 2015;6():266-

The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies
Dosani T, Carlsten M, Maric I, Landgren O
Blood cancer journal 2015;5():e321-

Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens
Childs Rw, Carlsten M
Nature reviews. Drug discovery 2015;14(7):487-98

A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma
Korde N, Carlsten M, Lee Mj, Minter A, Tan E, Kwok M, et al
Haematologica 2014;99(6):e81-3

Ultra-low dose interleukin-2 promotes immune-modulating function of regulatory T cells and natural killer cells in healthy volunteers
Ito S, Bollard Cm, Carlsten M, Melenhorst Jj, Biancotto A, Wang E, et al
Molecular therapy : the journal of the American Society of Gene Therapy 2014;22(7):1388-95

Doxorubicin sensitizes human tumor cells to NK cell- and T-cell-mediated killing by augmented TRAIL receptor signaling
Wennerberg E, Sarhan D, Carlsten M, Kaminskyy Vo, D'arcy P, Zhivotovsky B, et al
International journal of cancer 2013;133(7):1643-52

Selenite induces posttranscriptional blockade of HLA-E expression and sensitizes tumor cells to CD94/NKG2A-positive NK cells
Enqvist M, Nilsonne G, Hammarfjord O, Wallin Rp, Björkström Nk, Björnstedt M, et al
Journal of immunology (Baltimore, Md. : 1950) 2011;187(7):3546-54

Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34+ blasts in myelodysplastic syndrome
Carlsten M, Baumann Bc, Simonsson M, Jädersten M, Forsblom Am, Hammarstedt C, et al
Leukemia 2010;24(9):1607-16

Natural killer cell-mediated lysis of freshly isolated human tumor cells
Carlsten M, Malmberg Kj, Ljunggren Hg
International journal of cancer 2009;124(4):757-62

Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells
Carlsten M, Norell H, Bryceson Yt, Poschke I, Schedvins K, Ljunggren Hg, et al
Journal of immunology (Baltimore, Md. : 1950) 2009;183(8):4921-30

Regulation of interleukin-4 signaling by extracellular reduction of intramolecular disulfides
Curbo S, Gaudin R, Carlsten M, Malmberg Kj, Troye-blomberg M, Ahlborg N, et al
Biochemical and biophysical research communications 2009;390(4):1272-7

Estimation of the size of the alloreactive NK cell repertoire: studies in individuals homozygous for the group A KIR haplotype
Fauriat C, Andersson S, Björklund At, Carlsten M, Schaffer M, Björkström Nk, et al
Journal of immunology (Baltimore, Md. : 1950) 2008;181(9):6010-9

NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy
Malmberg Kj, Bryceson Yt, Carlsten M, Andersson S, Björklund A, Björkström Nk, et al
Cancer immunology, immunotherapy : CII 2008;57(10):1541-52

A short-term dietary supplementation with high doses of vitamin E increases NK cell cytolytic activity in advanced colorectal cancer patients
Hanson Mg, Ozenci V, Carlsten Mc, Glimelius Bl, Frödin Je, Masucci G, et al
Cancer immunology, immunotherapy : CII 2007;56(7):973-84

DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells
Carlsten M, Björkström Nk, Norell H, Bryceson Y, Van Hall T, Baumann Bc, et al
Cancer research 2007;67(3):1317-25

Frequent loss of HLA-A2 expression in metastasizing ovarian carcinomas associated with genomic haplotype loss and HLA-A2-restricted HER-2/neu-specific immunity
Norell H, Carlsten M, Ohlum T, Malmberg Kj, Masucci G, Schedvins K, et al
Cancer research 2006;66(12):6387-94

IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism
Malmberg Kj, Levitsky V, Norell H, De Matos Ct, Carlsten M, Schedvins K, et al
The Journal of clinical investigation 2002;110(10):1515-23

The core promoter of human thioredoxin reductase 1: cloning, transcriptional activity, and Oct-1, Sp1, and Sp3 binding reveal a housekeeping-type promoter for the AU-rich element-regulated gene
Rundlöf Ak, Carlsten M, Arnér Es
The Journal of biological chemistry 2001;276(32):30542-51

Prominent expression of the selenoprotein thioredoxin reductase in the medullary rays of the rat kidney and thioredoxin reductase mRNA variants differing at the 5' untranslated region
Rundlöf Ak, Carlsten M, Giacobini Mm, Arnér Es
The Biochemical journal 2000;347 Pt 3():661-8

Visa alla publikationer